These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

208 related items for PubMed ID: 6681824

  • 1. Morphologic features of the ductus arteriosus after prostaglandin E1 administration for ductus-dependent congenital heart defects.
    Park IS, Nihill MR, Titus JL.
    J Am Coll Cardiol; 1983 Feb; 1(2 Pt 1):471-5. PubMed ID: 6681824
    [No Abstract] [Full Text] [Related]

  • 2. [Prostaglandin treatment of ductus-dependent congenital heart defects].
    Olsson B, Björkhem G, Lundström NR.
    Lakartidningen; 1984 Oct 03; 81(40):3619-22. PubMed ID: 6541738
    [No Abstract] [Full Text] [Related]

  • 3. Prostaglandins and the management of congenital heart disease.
    Taylor WJ, Alpert BS.
    Am Fam Physician; 1982 Dec 03; 26(6):127-32. PubMed ID: 6890758
    [Abstract] [Full Text] [Related]

  • 4. The morphology of the human newborn ductus arteriosus: a reappraisal of its structure and closure with special reference to prostaglandin E1 therapy.
    Silver MM, Freedom RM, Silver MD, Olley PM.
    Hum Pathol; 1981 Dec 03; 12(12):1123-36. PubMed ID: 7199511
    [Abstract] [Full Text] [Related]

  • 5. [Anesthesia for neonates and young infants with ductus dependent cardiac malformations treated with prostaglandin E1].
    Fujii S, Nagai I, Yonei A, Sari A, Baba K.
    Masui; 1984 May 03; 33(5):545-9. PubMed ID: 6540818
    [No Abstract] [Full Text] [Related]

  • 6. [Treatment of ductus-dependent congenital heart diseases with prostaglandin E1].
    Lillquist K.
    Ugeskr Laeger; 1979 Jul 09; 141(28):1915-6. PubMed ID: 473414
    [No Abstract] [Full Text] [Related]

  • 7. Pharmacological manipulation of the ductus arteriosus.
    Silove ED.
    Arch Dis Child; 1986 Sep 09; 61(9):827-9. PubMed ID: 3767410
    [No Abstract] [Full Text] [Related]

  • 8. Failure of clinical response to prostaglandin E1 in a cyanotic infant with congenital absence of the ductus arteriosus.
    Hamilton WT, Lacina SJ, Bharati S, Lev M, Arcilla RA.
    Cathet Cardiovasc Diagn; 1982 Sep 09; 8(3):273-6. PubMed ID: 7201887
    [No Abstract] [Full Text] [Related]

  • 9. Evaluation of alprostadil (prostaglandin E1) in the management of congenital heart disease in infancy.
    Heymann MA, Clyman RI.
    Pharmacotherapy; 1982 Sep 09; 2(3):148-55. PubMed ID: 6763200
    [Abstract] [Full Text] [Related]

  • 10. Comments on the pharmacologic manipulation of the ductus arteriosus in newborns.
    Rowe RD.
    Adv Prostaglandin Thromboxane Res; 1978 Sep 09; 4():383-5. PubMed ID: 645513
    [No Abstract] [Full Text] [Related]

  • 11. The ductus arteriosus: why and how to manipulate its patency.
    Drummond WH, Bucciarelli RL, Gessner IH.
    J Fla Med Assoc; 1983 Sep 09; 70(9):788-93. PubMed ID: 6355376
    [No Abstract] [Full Text] [Related]

  • 12. Histopathology of the ductus arteriosus after prostaglandin E1 administration in ductus dependent cardiac anomalies.
    Gittenberger-de Groot AC, Moulaert AJ, Harinck E, Becker AE.
    Br Heart J; 1978 Mar 09; 40(3):215-20. PubMed ID: 637973
    [Abstract] [Full Text] [Related]

  • 13. Congenital heart disease and respiratory distress syndrome. Reversal of indomethacin closure of patent ductus arteriosus by prostaglandin therapy in a preterm infant.
    Strauss A, Modanlou HD, Gyepes M, Wittner R.
    Am J Dis Child; 1982 Oct 09; 136(10):934-6. PubMed ID: 6889810
    [Abstract] [Full Text] [Related]

  • 14. [Skeletal side effects of treatment with prostaglandin E1].
    Persigehl M, Hövels-Gürich H, von Bernuth G.
    Rofo; 1984 Oct 09; 141(4):427-30. PubMed ID: 6436918
    [Abstract] [Full Text] [Related]

  • 15. Prostaglandin E1 in neonates with critical congenital heart disease.
    Dungan WT, Norton JB, Readinger RI, Sotomora RF.
    J Ark Med Soc; 1982 Oct 09; 79(5):167-70. PubMed ID: 6183249
    [No Abstract] [Full Text] [Related]

  • 16. Clinical use of prostaglandins and prostaglandin synthetase inhibitors in cardiac problems of the newborn.
    Olley PM, Coceani F, Rowe RD, Swyer PR.
    Adv Prostaglandin Thromboxane Res; 1980 Oct 09; 7():913-6. PubMed ID: 6768235
    [No Abstract] [Full Text] [Related]

  • 17. Cardiovascular therapy in the newborn.
    Sandor GG.
    Clin Invest Med; 1985 Oct 09; 8(4):360-7. PubMed ID: 3907921
    [Abstract] [Full Text] [Related]

  • 18. [Use of prostaglandin E1 in ductus-dependent congenital cardiopathies].
    Marcial MB, Maluf M, Atik E, Vargas H, Baucia JA, Verginelli G.
    Arq Bras Cardiol; 1983 Jun 09; 40(6):383-6. PubMed ID: 6686760
    [No Abstract] [Full Text] [Related]

  • 19. [Prolonged prostaglandin E-1 therapy of newborn infants with congenital heart defects].
    Kertész E, Hencz P, Tekulics P, Beviz J, Száva J, Matkó I, Kovács G.
    Orv Hetil; 1980 May 18; 121(20):1197-9. PubMed ID: 7413203
    [No Abstract] [Full Text] [Related]

  • 20. Alprostadil (Prostin VR Pediatric Sterile Solution, The Upjohn Company).
    Roehl SL, Townsend RJ.
    Drug Intell Clin Pharm; 1982 Nov 18; 16(11):823-32. PubMed ID: 6756848
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.